AZN Astrazeneca Plc

11,268.00

0.00 (0.00%)

24 Apr 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Astrazeneca Plc	LSE:AZN	London	Ordinary Share	GB0009895292	ORD SHS $0.25

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	11,268.00	11,222.00	11,226.00				0.00	01:00:00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Pharmaceutical Preparations	45.81B	5.96B	3.8415	29.33	174.68B

AstraZeneca: Enhertu Phase 2 Trial Meets Primary Endpoint

27/01/2020 7:58am

Dow Jones News

Astrazeneca (LSE:AZN)
Historical Stock Chart

From Apr 2019 to Apr 2024

By Anthony O. Goriainoff

AstraZeneca PLC (AZN.LN) said on Monday that the Phase 2 trial for Enhertu, its gastric cancer drug, met its primary endpoint.

The U.K. pharmaceutical company said the trial met the primary endpoint of objective response rate and key secondary endpoint of overall survival in patients with previously treated HER2-positive metastatic gastric cancer compared to an investigator's choice of chemotherapy.

"Given the previous results seen in our HER2-positive development program and now in HER2-positive metastatic gastric cancer, we believe this antibody drug conjugate has the potential to redefine the treatment of patients with HER2-expressing cancers," the company said.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

January 27, 2020 02:43 ET (07:43 GMT)